

CLAIMS

1. Use of a pyrimidine nucleotide for the treatment of affections of the peripheral nervous system and/or for stimulating the regeneration of nerves.

5

2. Use according to claim 1, wherein the affections of the peripheral nervous system concern polyneuropathies, neuritides and/or myopathies.

3. Use according to claim 2, wherein the polyneuropathies, neuritides and myopathies concern degenerative diseases of the spinal column, diabetic polyneuropathies, polyneuropathies after alcohol abusos, other toxic polyneuropathies, facial nerve paresis, face neuralgias, multiple sclerosis, root neuritides, cervical syndrome, shoulder-arm syndrome, ischialgia, lumbago, intercostal neuralgia, trigeminus neuralgia and/or herpes zoster.

15

4. Use according to any previous claim, wherein the pyrimidine nucleotide is uridine-5'-monophosphate, uridine-5'-diphosphate, uridine-5'-triphosphate, cytidine-5'-monophosphate, cytidine-5'-diphosphate, or cytidine-5'-triphosphate.

5. Use according to claim 4, wherein the pyrimidine nucleotide is uridine-5'-monophosphate.

6. Use according to any previous claim, wherein the pyrimidine nucleotide is administered in a daily dose rate of 1 – 100 mg, preferably of 5 – 50 mg and most preferably of 7 to 40 mg.

7. Use of a pyrimidine nucleotide for the manufacture of a pharmaceutical composition for the treatment of affections of the peripheral nervous system and/or for the stimulation of the regeneration of nerves.

30

REPLACED BY
ART 19 AMDT

8. Pharmaceutical composition comprising a pyrimidine nucleotide as pharmaceutically active ingredient optionally together with physiologically acceptable carriers, adjuvants and/or diluents.
- 5 9. Pharmaceutical composition according to claim 8, wherein the single pharmaceutical composition contains the pyrimidine nucleotide in a concentration of 1 – 100 mg, preferably 5 – 50 mg and most preferably 7 – 40 mg.
- 10 10. Pharmaceutical composition according to claim 8 or 9, wherein the pharmaceutical composition is suitable for oral application or injection.

REPLACED BY
ART 19 AMDT